Telix Pharmaceuticals is trading 7.51% up now at $12.58 as U.S. equities recover following the Federal Reserve’s September 16 rate decision.
- The S&P 500 and Nasdaq are both gaining more than 0.5%, supporting a broad risk-on rebound.
- Recent volatility followed FDA approval of Pixclara, which previously lifted Telix shares.
- No new company-specific announcement explains the September 17 advance.